NEW YORK, Jan. 23 - PanTherix and Genome Therapeutics said today they have entered a research collaboration in the search for drug targets.
Genome Therapeutics will use PanTherix's protein structure determination technology to unlock the three-dimensional structures of its bacterial targets in its anti-infective drug discovery program, the company said.
Financial terms of the agreement were not disclosed.
Click here for more information.